Online citations, reference lists, and bibliographies.

Combined Cytoreductive Surgery And Perioperative Intraperitoneal Chemotherapy For The Treatment Of Advanced Ovarian Cancer

A. Tentes, N. Courcoutsakis, Panos Prasopoulos
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Ovarian cancer is the leading cause of death from gynecologic cancer and the fifth cause of cancer deaths in women in developed countries (Yancik, 1993; Cannistra, 1993). The number of deaths seems to increase the last few years. More than 70% of the patients with ovarian cancer have advanced disease at the time of initial diagnosis because they remain asymptomatic in early stages (Roberts, 1996). Ovarian cancer is the most frequent intraceolomic malignancy presenting with peritoneal spread. In the past debulking surgery combined with systemic chemotherapy offered long-term survival in less than 10% of the patients (Smith & Day, 1979). The standard treatment of advanced ovarian cancer is cytoreductive surgery followed by systemic chemotherapy (Hacker et al, 1983; Neijt et al, 1991; Hoskins et al, 1992). Despite systemic chemotherapy based on platinum and taxanes 5 and 10-year survival rate do not exceed 20% and 10% respectively because the majority of the patients develop recurrence (Mc Guire & Ozols, 1998; Piccart et al, 2000). The disease remains characteristically confined to the peritoneal surfaces for most of its natural course (Bergmann, 1996). Surgical resection of the tumor may not be complete and microscopic or even macroscopic residual tumor may be left behind. In these situations the intraperitoneal route of administration of cytostatic drugs is a logical approach. Patients with diseases that have similar biological behavior to ovarian cancer are offered significant survival benefit when they are treated with perioperative intraperitoneal chemotherapy integrated in cytoreductive surgery. In pseudomyxoma peritonei (Sugarbaker, 2006), peritoneal sarcomatosis (Rossi et al, 2004), peritoneal mesothelioma (Yan et al, 2007), colorectal cancer with peritoneal dissemination (Elias et al, 2009; Mahteme et al, 2004; Verwaal et al, 2008), as well as in gastric cancer with peritoneal carcinomatosis (Yonemura et al, 1996; Yu et al, 1998) survival is improved with this treatment strategy. The last two decades the method has been used in ovarian cancer with promising results.
This paper references
10.1245/ASO.2005.11.030
Bowel Complications in 203 Cases of Peritoneal Surface Malignancies Treated With Peritonectomy and Closed-Technique Intraperitoneal Hyperthermic Perfusion
R. Younan (2005)
10.1200/JCO.2004.10.012
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
O. Glehen (2004)
10.1016/S0168-8278(03)00141-7
Epidemiology of hepatitis B in Europe and worldwide.
M. Alter (2003)
10.1016/J.YGYNO.2004.01.029
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
D. Chi (2004)
10.1016/S0264-410X(99)00456-9
Hepatitis B epidemiology in Asia, the Middle East and Africa.
F. André (2000)
10.1002/1522-2586(200008)12:2<269::AID-JMRI9>3.0.CO;2-G
Extrahepatic abdominal imaging in patients with malignancy: comparison of MR imaging and helical CT in 164 patients.
R. N. Low (2000)
Handbook for the Integration of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy into the Surgical Management of Gastrointestinal and Gynecologic Malignancies
PH Sugarbaker (2005)
Health Care Epidemiology
E. S. Wong (2004)
10.1007/s003300100998
Peritoneal carcinomatosis
V. Raptopoulos (2014)
10.1038/scientificamerican0491-116
[Hepatitis B virus].
P. Tiollais (1987)
10.1002/JSO.20597
Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.
S. Rufián (2006)
Epidemiology of hepatitis B in the Islamic Republic of Iran.
M. Zali (1996)
10.1245/ASO.2006.03.045
Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
M. Deraco (2006)
Primary Cytoreductive Surgery for Epithelial Ovarian Cancer
N. Hacker (1983)
10.1245/ASO.2006.05.041
Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy: Results of a Prospective Study
C. Brigand (2006)
10.1097/00000658-199109000-00014
Second-look Surgery for Colorectal Cancer
E. Martin (1991)
10.1186/1477-7819-2-21
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer
P. Piso (2004)
10.1055/s-2008-1040427
Hepatitis B: evolving epidemiology and implications for control.
H. Margolis (1991)
10.1016/S0039-6109(05)70163-8
Staging of gynecologic malignancies.
F. Odicino (2001)
Principles of molecular cell biology of cancer : Growth factors related to transformation
AB Roberts (1989)
10.1016/S0090-8258(03)00278-6
Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.
S. Eisenkop (2003)
10.1016/s1055-3207(03)00048-6
Peritonectomy procedures.
P. Sugarbaker (1996)
10.1016/S0020-7292(06)60033-7
Carcinoma of the Ovary
A. Heintz (2006)
CAUSES OF CIRRHOSIS IN A SERIES OF PATIENTS AT A UNIVERSITY HOSPITAL IN TEHRAN
K. Azimi (2002)
10.1053/EJSO.2002.1380
Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer.
A. Tentes (2003)
10.1016/j.amjsurg.2008.06.037
Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy.
Nathaniel P. Reuter (2008)
Epidemiology of viral hepatitis among Iranian population--a viral marker study.
H. Farzadegan (1980)
Seroprevalence of hepatitis B in Nahavand, Islamic Republic of Iran.
A. Alizadeh (2006)
10.1037/e548742006-001
Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis.
A. L. Panlilio (2005)
10.1007/978-1-4613-1247-5_18
Methodologic considerations in treatment using intraperitoneal chemotherapy.
A. Averbach (1996)
10.1007/978-1-4613-1247-5_4
Peritoneal-plasma barrier.
P. Jacquet (1996)
10.1097/PPO.0b013e3181a58ec3
Imaging of Peritoneal Carcinomatosis
S. González-Moreno (2009)
10.1200/JCO.2008.19.7160
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
D. Elias (2009)
HEPATITIS B IN IRAN
S. Merat (2000)
10.1245/s10434-008-9966-2
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer
V. Verwaal (2008)
10.1007/s002800051093
Successful management of microscopic residual disease in large bowel cancer
P. Sugarbaker (1999)
10.1007/s00261-008-9464-9
64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings
D. Marin (2008)
Hepatitis B surface antigen and anti-hepatitis C antibodies among blood donors in the Islamic Republic of Iran.
A. A. Ghavanini (2000)
10.7150/IJMS.2.36
Natural History and Clinical Consequences of Hepatitis B Virus Infection
C. Pan (2005)
10.1007/978-1-4613-1247-5_17
Radiology of peritoneal carcinomatosis.
A. Archer (1996)
10.1016/J.EJSO.2006.03.002
Quantitative prognostic indices in peritoneal carcinomatosis.
F. Gilly (2006)
10.1016/S0002-9378(94)70090-7
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.
W. Hoskins (1994)
10.1002/cncr.20192
Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis
C. Rossi (2004)
10.1007/s00268-004-7461-x
Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer
C. Zanon (2004)
10.14219/jada.archive.2004.0019
Guidelines for infection control in dental health-care settings--2003.
W. Kohn (2003)
10.1046/J.1440-1746.2000.0150121356.X
Chronic hepatitis B virus infection in Asian countries.
I. Merican (2000)
10.1016/0277-5379(91)90011-2
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
J. Neijt (1991)
10.1016/S0959-8049(98)00375-X
Quantitative methodologies for selection of patients with recurrent abdominopelvic sarcoma for treatment.
B. Berthet (1999)
Combined Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for the Treatment of Advanced Ovarian Cancer, Ovarian Cancer - Clinical and Therapeutic Perspectives, Dr
Antonios-Apostolos K. Tentes (2012)
10.2169/NAIKA.106.428
2. Hepatitis B
S. Takahashi (2007)
10.3109/00016346609158447
Carcinoma of the Ovary
F. Bergman (1966)
Harrison's Principles of Internal Medicine
edotir's Eugene Braunwald... (1950)
10.1002/CNCR.2820710205
Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
R. Yancik (1993)
10.1002/JSO.20049
Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement.
E. de Bree (2004)
10.1016/0090-8258(92)90100-W
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.
W. Hoskins (1992)
10.1046/J.1365-2168.2000.01571.X
Results of treatment of 33 patients with peritoneal mesothelioma
G. Sebbag (2000)
10.1002/cncr.23553
Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer
A. di Giorgio (2008)
Growth factors and transformation.
A. Roberts (1986)
10.1111/J.1525-1438.2006.00580.X
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
10.1111/J.1525-1438.2003.13319.X
Long‐term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum
M. Look (2003)
10.1002/cncr.21708
Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion
S. Kusamura (2006)
10.1148/rg.305105073
Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer.
S. Kyriazi (2010)
10.2214/AJR.10.4687
Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT.
Yoko Satoh (2011)
10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy
D. Elias (2001)
The epidemiology of viral hepatitis in the united states
Alter Mj (1994)
10.1016/J.YGYNO.2004.05.044
Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer.
K. Ryu (2004)
10.1097/00000658-199809000-00007
Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer.
W. Yu (1998)
10.1177/107327489600300205
Cytoreductive Surgery in Ovarian Cancer: Why, When, and How?
Roberts (1996)
10.1148/RG.241035178
From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation.
P. Woodward (2004)
10.1016/0002-9378(79)90824-X
Rewiew of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute.
J. P. Smith (1979)
[Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed].
J. Esquivel (1999)
REASSESSMENT OF THE ROLE OF HEPATITIS B AND C VIRUSES IN POST NECROTIC CIRRHOSIS AND CHRONIC HEPATITIS IN SOUTHERN IRAN
B. L. Kamran (1999)
10.1016/S0264-410X(98)00415-0
Strategies to prevent and control hepatitis B and C virus infections: a global perspective.
E. Mast (1999)
10.1245/s10434-007-9691-2
Pseudomyxoma Peritonei: Clinical Pathological and Biological Prognostic Factors in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
D. Baratti (2007)
10.1007/s00330-007-0736-5
Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI
R. Forstner (2007)
Peritoneal carcinomatosis from gastrointestinal malignancy: natural history and new prospects for management.
P. Jacquet (1994)
10.1700/499.5920
Cytoreductive surgery and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer.
A. Tentes (2010)
10.3748/WJG.V12.I32.5211
Preliminary report of hepatitis B virus genotype prevalence in Iran.
S. Alavian (2006)
10.1038/sj.bjc.6601586
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study
H. Mahteme (2004)
10.1016/S1470-2045(05)70539-8
New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
P. Sugarbaker (2006)
10.1093/JNCI/92.9.699
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
M. Piccart (2000)
Handbook for the Integration of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy into the Surgical Management of Gastrointestinal and Gynecologic Malignancies
PH Sugarbaker (2005)
10.1007/978-1-4613-1247-5_23
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.
P. Jacquet (1996)
[Carcinoma of the ovary].
C. A. Salvatore (1960)
Chemotherapy of advanced ovarian cancer.
Mcguire Wp (1998)
Recommendations for preventing transmission of infections among chronic hemodialysis patients
M. Alter (2001)
10.1016/S0039-6060(96)80145-0
Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination.
Y. Yonemura (1996)
10.1245/s10434-009-0878-6
Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer
W. Ceelen (2012)
10.1245/s10434-006-9169-7
Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma†
T. Yan (2006)
10.1016/S1055-3207(03)00035-8
Effective therapy for peritoneal dissemination in gastric cancer.
Y. Yonemura (2003)
10.1016/J.EJSO.2006.03.011
Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan.
F. Raspagliesi (2006)
10.1245/ASO.2003.01.018
Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure and Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis: Morbidity and Mortality Analysis of 216 Consecutive Procedures
O. Gléhen (2003)
10.1007/s10434-999-0790-0
Morbidity and Mortality Analysis of 200 Treatments With Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy Using the Coliseum Technique
A. D. Stephens (1999)
10.1056/nejmra041842
Cancer of the ovary.
S. Cannistra (2004)
The minimal importance of the hollow viscera to peritoneal transport during peritoneal dialysis in the rat.
J. Rubin (1988)
10.1016/J.YGYNO.2007.03.019
Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
J. H. Bae (2007)
10.1002/JSO.10270
Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer.
K. Stamou (2003)
10.1097/01.sla.0000152015.76731.1f
Long-term Survival Following Treatment of Pseudomyxoma Peritonei: An Analysis of Surgical Therapy
T. Miner (2005)
10.1148/RADIOL.2232011081
Peritoneal metastases: detection with spiral CT in patients with ovarian cancer.
F. Coakley (2002)
10.1007/s004230050246
Management of peritoneal-surface malignancy: the surgeon’s role
P. Sugarbaker (1999)
Cytoreductive approach to peritoneal carcinomatosis: peritonectomy and intraperitoneal chemotherapy
PH Sugarbaker (1991)
Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin.
E. de Bree (2003)
10.1200/JCO.20.5.1248
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
R. Bristow (2002)
10.1016/0020-7292(92)90942-C
Meta‐analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis?
R. Hunter (1992)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar